Non-steroidal anti-inflammatory drugs and prostate cancer progression

International Journal of Cancer

Volumn 77, Issue 4, 1998, Pages 511-515

  Norrish, Alan E ^a   Jackson, Rodney T ^a   McRae, Colin U ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PREVENTION; CANCER RISK; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; FAT INTAKE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; DIETARY FATS; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SOCIOECONOMIC FACTORS;

EID: 0031823804     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980812)77:4<511::AID-IJC6>3.0.CO;2-X     Document Type: Article

References (23)

1. ANDERSSON, S.-O., WOLK, A., BERGSTROM, R. GIOVANNUCCI E., LINDGREN, C., BARON, J. and ADAMI, H.-O., Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden. Int. J. Cancer., 68, 716-722 (1996).
2. BARON, J.A. Aspirin and cancer. Prev. Med., 24, 121-124 (1995).
3. BURLINGAME, B.A., MILLIGAN, G.C., APIMERIKA, D.E. and ARTHUR, J.M., The Concise New Zealand Food Composition Tables, New Zealand Institute for Crop and Food Research Limited, Department of Health, Palmerston North, New Zealand (1993).
4. CHAUDRY, A.A., WAHLE, K.W.J., MCCLINTON, S. and MOFFAT, L.E.F., Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int. J. Cancer, 57, 176-180 (1994).
5. EARNEST, D.L., HIXSON, L.J. and ALBERTS, D.S., Piroxicam and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J. Cell. Biochem., 161 (suppl), 156-166 (1992).
6. EGAN, K.M., STAMPFER, M.J., GIOVANNUCCI, E., ROSNER, B.A. and COLDITZ, G.A., Prospective study of regular aspirin use and the risk of breast cancer. J. nat. Cancer Inst., 88, 941-942 (1996).
7. GIOVANNUCCI, E., ASCHERIO, A., RIMM, E.B., STAMPFER, M.J., COLDITZ, G.A. and WILLETT, W.C., Intake of carotenoids and retinol in relation to risk, of prostate cancer. J. nat. Cancer Inst., 87, 1767-1776 (1995).
8. GIOVANNUCCI, E., RIMM, E.B., COLDITZ, G.A., STAMPFER, M.J., ASCHERIO, A., CHUTE, C.C. and WILLETT, W.C., A prospective study of dietary fat and risk of prostate cancer. J. nat. Cancer Inst., 85, 1571-1579 (1992).
9. HARRIS, R.E., NAMBOODIRI, K.K. and FARRAR, W.B., Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology, 7, 203-205 (1996).
10. JOHNSTON, R., A revision of socio-economic indices for New Zealand, New Zealand Council for Educational Research, Wellington (1983).
11. KOLONEL, L., Nutrition and prostate cancer. Cancer Causes Control, 7, 83-94 (1996).
12. LUPULESCU, A., Prostaglandins, their inhibitors and cancer. Prostaglandins Leuko. Essent. Fatty Acids, 54, 83-94 (1996).
13. PAGANINI-HILL, A., CHAO, A., Ross, R.K. and HENDERSON, B.E., Aspirin use and chronic diseases: a cohort study of the elderly. Brit. Med. J., 299, 1247-1250, (1989).
14. PICOT, D., LOLL, P.J. and GARAVITO, M., The structure of the membrane protein prostaglandin H2 synthase-1 determined by X-ray crystallography. Nature (Lond.), 367, 243-249 (1994).
15. ROSE, D.P. and CONNOLLY, J.M., Effects of fatty acids and eicosanoid synthesis on the growth of two prostate cancer cell lines. Prostate, 18, 243-254 (1991).
16. ROSE, D.P. and CONNOLLY, J.M., Dietary fat, fatty acids and prostate cancer. Lipids, 27, 798-803 (1992).
17. SCHREINEMACHERS, D.M. and EVERSON, R.B., Aspirin use and lung, colon and breast cancer incidence in a prospective study. Epidemiology, 5, 138-146 (1994).
18. SMITH, W.L., Prostanoid biosynthesis and mechanisms of action. Amer. J. Physiol., 263, F181-F191 (1992).
19. THUN, M.J., NAMBOODIRI, M.M., CALLE, E.E., FLANDERS, W.D. and CLARK, W.H., Aspirin use and risk of fatal cancer. Cancer Res., 53, 1322-1327 (1993).
20. TJANDRAWINATA, R.R., DAHIYA, R. and HUGHES-FULFORD, M., Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Brit. J. Cancer, 75, 1111-1118 (1997).
21. VILJOEN, T.C., VAN ASWEGEN, C.H. and DU PLESSIS, D.J., Influence of acetylsalicylic acid and metabolites on DU-145 prostatic cancer cell proliferation. Oncology, 52, 465-469 (1995).
22. WEST, D.W., SLATTERY, M.L., ROBISON, L.M., FRENCH, T.K. and MAHONEY, A.W., Adult dietary intake and prostate risk in Utah: a case-control study with special reference to aggressive tumours. Cancer Causes Control, 2, 85-94 (1991).
23. WILLET, W., Nutritional epidemiology, Oxford University Press, Oxford (1990).